Growth inhibition of human cancer cells by 5-aza-2′-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status

Molecular Cancer Therapeutics

Volumn 8, Issue 4, 2009, Pages 779-785

  Xiong, Jingbo ^a,b   Epstein, Richard J ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ARF PROTEIN; PROTEIN P14; PROTEIN P16; SMALL INTERFERING RNA; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DRUG DERIVATIVE; MESSENGER RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; COLORECTAL CANCER; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEMETHYLATION; DRUG CYTOTOXICITY; DRUG EFFECT; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; TRANSGENE; UPREGULATION; BREAST TUMOR; CELL CYCLE; CELL PROLIFERATION; COLORECTAL TUMOR; DNA METHYLATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; AZACITIDINE; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 66449127105     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0926     Document Type: Article

References (46)

1. Bender CM, Pao MM, Jones PA. Inhibition of DNA methylation by 5- aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 1998;58:95-101. (Pubitemid 28027723)
2. Timmermann S, Hinds PW, Munger K. Re-expression of endogenous p16INK4a in oral squamous cell carcinoma lines by 5-aza-2′-deoxycytidine treatment induces a senescence-like state. Oncogene 1998;17: 3445-3453 (Pubitemid 29050679)
3. Missiaglia E, Donadelli M, Palmieri M, et al. Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2′-deoxycytidine treatment is associated with activation of the interferon signalling pathway. Oncogene 2005;24:199-211. (Pubitemid 40143879)
4. Badal V, Menendez S, Coomber D, et al. Regulation of the p14ARF promoter by DNA methylation. Cell Cycle 2008;7:112-119
5. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001;2:731-737 (Pubitemid 33679835)
6. Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/p16/ MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995;55:4525-4530
7. Esteller M, Tortola S, Toyota M, et al. Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res 2000;60:129-133 (Pubitemid 30058742)
8. Nielsen NH, Roos G, Emdin SO, et al. Methylation of the p16(INK4a) tumor suppressor gene 5′-CpG island in breast cancer. Cancer Lett 2001;163:59-69. (Pubitemid 32121831)
9. Schmelz K, Sattler N, Wagner M, et al. Induction of gene expression by 5-aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms. Leukemia 2005;19:103-111 (Pubitemid 40090084)
10. Zhu WG, Dai Z, Ding H, et al. Increased expression of unmethylated CDKN2D by 5-aza-2′-deoxycytidine in human lung cancer cells. Oncogene 2001;20:7787-7796 (Pubitemid 33121952)
11. Soengas MS, Capodieci P, Polsky D, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001;409:207-211 (Pubitemid 32144287)
12. Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci U S A 1994;91:11797-11801 (Pubitemid 24985095)
13. Zhu WG, Hileman T, Ke Y, et al. 5-Aza-2′-deoxycytidine activates the p53/p21WAF1/CIP1 pathway to inhibit cell proliferation. J Biol Chem 2004;279:15161-15166 (Pubitemid 38618911)
14. Covey JM, D'Incalci M, Tilchen EJ, et al. Differences in DNA damage produced by incorporation of 5-aza-2′-deoxycytidine or 5,6-dihydro-5-azacytidine into DNA of mammalian cells. Cancer Res 1986;46:5511-5517 (Pubitemid 17177937)
15. Palii SS, Van Emburgh BO, Sankpal UT, et al. DNA methylation inhibitor 5-aza-2′-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3b. Mol Cell Biol 2008;28:752-771
16. Paz MF, Fraga MF, Avila S, et al. A systematic profile of DNA methylation in human cancer cell lines. Cancer Res 2003;63:1114-1121 (Pubitemid 36278446)
17. Zheng S, Chen P, McMillan A, et al. Correlations of partial and extensive methylation at the p14(ARF) locus with reduced mRNA expression in colorectal cancer cell lines and clinicopathological features in primary tumors. Carcinogenesis 2000;21:2057-2064
18. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-9826 (Pubitemid 26296693)
19. Xiong J, Fan S, Meng Q, et al. BRCA1 inhibition of telomerase activity in cultured cells. Mol Cell Biol 2003;23:8668-8690 (Pubitemid 37433370)
20. Oruetxebarria I, Venturini F, Kekarainen T, et al. p16INK4a is required for HSNF5 chromatin remodeler-induced cellular senescence in malignant rhabdoid tumor cells. J Biol Chem 2004;279:3807-3816 (Pubitemid 38140626)
21. Eymin B, Claverie P, Salon C, et al. p14ARF activates a TIP60-dependent and p53-independent ATM/ATR/CHK pathway in response to genotoxic stress. Mol Cell Biol 2006;26:4339-4350 (Pubitemid 43788032)
22. O'Connor PM. Mammalian G1 and G2 phase checkpoints. Cancer Surv 1997;29:151-182
23. Yogev O, Saadon K, Anzi S, et al. DNA damage-dependent translocation of B23 and p19 ARF is regulated by the Jun N-terminal kinase pathway. Cancer Res 2008;68:1398-1406
24. Schmitt CA, Fridman JS, Yang M, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002;109:335-346 (Pubitemid 34606876)
25. Bardeesy N, Bastian BC, Hezel A, et al. Dual inactivation of Rb and p53 pathways in Ras-induced melanomas. Mol Cell Biol 2001; 21:2144-2153 (Pubitemid 32479635)
26. Zhang Y, Wang Z, Ahmed F, et al. Down-regulation of jagged-1 induces cell growth inhibition and S phase arrest in prostate cancer cells. Int J Cancer 2006;119:2071-2077 (Pubitemid 44423663)
27. Kanda T, Tada M, Imazeki F, et al. 5-Aza-2′-deoxycytidine sensitizes hepatoma and pancreatic cancer cell lines. Oncol Rep 2005;14:975-979
28. Halloran CM, Ghaneh P, Shore S, et al. 5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4a greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells. J Gene Med 2004;6:514-525 (Pubitemid 40228067)
29. Schmelz K, Wagner M, Dorken B, et al. 5-Aza-2′-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53- independent apoptosis in myeloid leukemia. Int J Cancer 2005;114: 683-695 (Pubitemid 40344429)
30. Schneider-Stock R, Diab-Assef M, Rohrbeck A, et al. 5-Aza-cytidine is a potent inhibitor of DNA methyltransferase 3a and induces apoptosis in HCT-116 colon cancer cells via GADD45- and p53-dependent mechanisms. J Pharmacol Exp Ther 2005;312:525-536 (Pubitemid 40189549)
31. Sherr CJ, Bertwistle D, DEN Besten W, et al. p53-dependent and -independent functions of the ARF tumor suppressor. Cold Spring Harb Symp Quant Biol 2005;70:129-137 (Pubitemid 44124864)
32. Yang Q, Shan L, Yoshimura G, et al. 5-Aza-2′-deoxycytidine induces retinoic acid receptor β2 demethylation, cell cycle arrest and growth inhibition in breast carcinoma cells. Anticancer Res 2002;22:2753-2756 (Pubitemid 36069308)
33. Morita S, Iida S, Kato K, et al. The synergistic effect of 5-aza-2′-deoxycytidine and 5-fluorouracil on drug-resistant tumors. Oncology 2006;71: 437-445
34. Plumb JA, Strathdee G, Sludden J, et al. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the HMHL1 gene promoter. Cancer Res 2000;60:6039-6044
35. Arnold CN, Goel A, Boland CR. Role of HMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 2003;106:66-73. (Pubitemid 36750389)
36. Fujita H, Kato J, Horii J, et al. Decreased expression of HMLH1 correlates with reduced 5-fluorouracil-mediated apoptosis in colon cancer cells. Oncol Rep 2007;18:1129-1137
37. Van Rijnsoever M, Elsaleh H, Joseph D, et al. CpG island methylator phenotype is an independent predictor of survival benefit from5-fluorouracil in stage III colorectal cancer. Clin Cancer Res 2003;9:2898-2903 (Pubitemid 36993247)
38. Gifford G, Paul J, Vasey PA, et al. The acquisition of HMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 2004;10:4420-4426 (Pubitemid 38878884)
39. Casorelli I, Russo MT, Bignami M. Role of mismatch repair and mgmt in response to anticancer therapies. Anticancer Agents Med Chem2008; 8:368-380
40. Wang H, Zhao Y, Li L, et al. An ATM- and Rad3-related (ATR) signaling pathway and a phosphorylation-acetylation cascade are involved in activation of p53/p21WAF1/CIP1 in response to 5-aza-2′-deoxycytidine treatment. J Biol Chem 2008;283:2564-2574
41. Karpf AR, Moore BC, Ririe TO, et al. Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza- 2′-deoxycytidine. Mol Pharmacol 2001;59:751-757 (Pubitemid 32274003)
42. Tomita Y, Marchenko N, Erster S, et al. WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J Biol Chem 2006;281:8600-8606 (Pubitemid 43847963)
43. Macip S, Igarashi M, Berggren P, et al. Influence of induced reactive oxygen species in p53-mediated cell fate decisions. Mol Cell Biol 2003;23: 8576-8585 (Pubitemid 37433363)
44. Rodrigues NR, Rowan A, Smith ME, et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A 1990;87:7555-7559 (Pubitemid 20341755)
45. Jiemjit A, Fandy TE, Carraway H, et al. p21(WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage. Oncogene 2008;27: 3615-3623
46. Nieto M, Samper E, Fraga MF, et al. The absence of p53 is critical for the induction of apoptosis by 5-aza-2′-deoxycytidine. Oncogene 2004;23:735-743 (Pubitemid 38241274)